Literature DB >> 12654810

The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model.

Priti Kumar1, Rama Rao Amara, Vijay Kumar Challu, Vineet Kumar Chadda, Vijaya Satchidanandam.   

Abstract

The search to identify Mycobacterium tuberculosis antigens capable of conferring protective immunity against tuberculosis has received a boost owing to the resurgence of tuberculosis over the past two decades. It has long been recognized that lymphoid cells are required for protection against M. tuberculosis. While traditionally the CD4(+) populations of T cells were believed to predominantly serve this protective function, a pivotal role for CD8(+) T cells in this task has been increasingly appreciated. We show that the 50- to 55-kDa Apa protein, specified by the Rv1860 gene of M. tuberculosis, can elicit both lymphoproliferative response and gamma interferon (IFN-gamma) production from peripheral blood mononuclear cells (PBMC) of purified protein derivative (PPD)-positive individuals, with significant differences recorded in the levels of responsiveness between PPD-positive healthy controls and pulmonary tuberculosis patients. Flow cytometric analysis of whole blood stimulated with the recombinant Apa protein revealed a sizeable proportion of CD8(+) T cells in addition to CD4(+) T cells contributing to IFN-gamma secretion. PBMC responding to the Apa protein produced no interleukin-4, revealing a Th1 phenotype. A DNA vaccine and a poxvirus recombinant expressing the Apa protein were constructed and tested for their ability to protect immunized guinea pigs against a challenge dose of virulent M. tuberculosis. Although the DNA vaccine afforded little protection, the poxvirus recombinant boost after DNA vaccine priming conferred a significant level of protective immunity, bringing about a considerable reduction in mycobacterial counts from the challenge bacilli in spleens of immunized guinea pigs, a result comparable to that achieved by BCG vaccination.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654810      PMCID: PMC152084          DOI: 10.1128/IAI.71.4.1929-1937.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis.

Authors:  I M Orme
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

2.  Responsiveness to live M. tuberculosis, and common antigens, of sonicate-stimulated T cell lines from normal donors.

Authors:  G A Rook; J Steele; S Barnass; J Mace; J L Stanford
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

Review 3.  Correlates of protective immunity to Mycobacterium tuberculosis in humans.

Authors:  J J Ellner; C S Hirsch; C C Whalen
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

4.  IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis.

Authors:  D Förtsch; M Röllinghoff; S Stenger
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  Possible role of helper and cytolytic T cells in mycobacterial infections.

Authors:  S H Kaufmann; S Chiplunkar; I Flesch; G De Libero
Journal:  Lepr Rev       Date:  1986-12       Impact factor: 0.537

Review 6.  Cellular immunity.

Authors:  G B Mackaness; R V Blanden
Journal:  Prog Allergy       Date:  1967

7.  Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction.

Authors:  J R David
Journal:  Proc Natl Acad Sci U S A       Date:  1966-07       Impact factor: 11.205

8.  Deglycosylation of the 45/47-kilodalton antigen complex of Mycobacterium tuberculosis decreases its capacity to elicit in vivo or in vitro cellular immune responses.

Authors:  F Romain; C Horn; P Pescher; A Namane; M Riviere; G Puzo; O Barzu; G Marchal
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

9.  Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells.

Authors:  I Müller; S P Cobbold; H Waldmann; S H Kaufmann
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

10.  Optimization of whole blood antigen-specific cytokine assays for CD4(+) T cells.

Authors:  L E Nomura; J M Walker; H T Maecker
Journal:  Cytometry       Date:  2000-05-01
View more
  24 in total

1.  Genetic toggling of alkaline phosphatase folding reveals signal peptides for all major modes of transport across the inner membrane of bacteria.

Authors:  Matthew Marrichi; Luis Camacho; David G Russell; Matthew P DeLisa
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

2.  Surface proteome of "Mycobacterium avium subsp. hominissuis" during the early stages of macrophage infection.

Authors:  Michael McNamara; Shin-Cheng Tzeng; Claudia Maier; Li Zhang; Luiz E Bermudez
Journal:  Infect Immun       Date:  2012-03-05       Impact factor: 3.441

3.  Expression library immunization confers protection against Mycobacterium avium subsp. paratuberculosis infection.

Authors:  J F Huntley; J R Stabel; M L Paustian; T A Reinhardt; J P Bannantine
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Mycobacterium tuberculosis conserved hypothetical protein rRv2626c modulates macrophage effector functions.

Authors:  Nasreena Bashir; Fozia Kounsar; Sangita Mukhopadhyay; Seyed E Hasnain
Journal:  Immunology       Date:  2010-02-26       Impact factor: 7.397

5.  A single dose of a DNA vaccine encoding apa coencapsulated with 6,6'-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice.

Authors:  Dyego Carlétti; Denise Morais da Fonseca; Ana Flávia Gembre; Ana Paula Masson; Lívia Weijenborg Campos; Luciana C C Leite; Andréa Rodrigues Pires; Joseli Lannes-Vieira; Célio Lopes Silva; Vânia Luiza Deperon Bonato; Cynthia Horn
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

6.  A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice.

Authors:  Jose C Ferraz; Evangelos Stavropoulos; Min Yang; Steve Coade; Clara Espitia; Douglas B Lowrie; M Joseph Colston; Ricardo E Tascon
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

7.  Bacterial protein-O-mannosylating enzyme is crucial for virulence of Mycobacterium tuberculosis.

Authors:  Chia-Fang Liu; Laure Tonini; Wladimir Malaga; Mathilde Beau; Alexandre Stella; David Bouyssié; Mary C Jackson; Jérôme Nigou; Germain Puzo; Christophe Guilhot; Odile Burlet-Schiltz; Michel Rivière
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-02       Impact factor: 11.205

8.  The Secreted Protein Rv1860 of Mycobacterium tuberculosis Stimulates Human Polyfunctional CD8+ T Cells.

Authors:  Vijaya Satchidanandam; Naveen Kumar; Sunetra Biswas; Rajiv S Jumani; Chandni Jain; Rajni Rani; Bharti Aggarwal; Jaya Singh; Mohan Rao Kotnur; Anand Sridharan
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

9.  Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients.

Authors:  Anbarasu Deenadayalan; Darragh Heaslip; Adhilakshmi Aavudaiyappan Rajendiran; Banurekha Vaithilingam Velayudham; Sheela Frederick; Hong-Liang Yang; Karen Dobos; John T Belisle; Alamelu Raja
Journal:  Mol Cell Proteomics       Date:  2009-12-22       Impact factor: 5.911

10.  Proteomic profiling of Mycobacterium tuberculosis identifies nutrient-starvation-responsive toxin-antitoxin systems.

Authors:  Jakob Albrethsen; Jeppe Agner; Sander R Piersma; Peter Højrup; Thang V Pham; Karin Weldingh; Connie R Jimenez; Peter Andersen; Ida Rosenkrands
Journal:  Mol Cell Proteomics       Date:  2013-01-23       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.